25391-59-7

Usage

Uses

Used in Organic Synthesis:
2-Hydroxy-5-iodo-3-nitropyridine is used as a building block in organic synthesis for the creation of various pharmaceuticals and agrochemicals. Its functional groups allow for further chemical reactions and modifications, making it a valuable component in the development of new compounds with specific therapeutic or agricultural properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-Hydroxy-5-iodo-3-nitropyridine serves as a key intermediate in the synthesis of pharmaceuticals. Its unique structure and reactivity enable the design and synthesis of novel drug candidates with potential therapeutic applications.
Used in Dye and Pigment Production:
2-Hydroxy-5-iodo-3-nitropyridine is utilized in the production of dyes and pigments due to its chemical properties. Its ability to form colored compounds makes it suitable for use in various industries, including textiles, plastics, and printing inks.
Used in Material Science:
2-Hydroxy-5-iodo-3-nitropyridine may have potential applications in material science, where its unique structural properties and reactivity can be harnessed to develop new materials with specific properties. This can include the creation of advanced materials for use in electronics, coatings, or other high-tech applications.

InChI:InChI=1/C5H3IN2O3/c6-3-1-4(8(10)11)5(9)7-2-3/h1-2H,(H,7,9)

Upstream product

• 20511-12-0 2-amino-5-iodopyridine 
• 6332-56-5 2-hydroxy-3-nitropyridine 
• 5470-18-8 2-Chloro-3-nitropyridine 
• 6332-56-5 3-nitropyridone 

Downstream Products

• 426463-05-0 2-chloro-5-iodo-3-nitro-pyridine 
• 1382936-41-5 C₂₀H₂₁ClN₂O₄ 
• 1382936-42-6 C₁₆H₁₃ClN₂O₄ 
• 1382936-39-1 C₁₅H₁₄ClIN₂O₃ 
• 1382936-40-4 C₁₅H₁₂ClIN₂O₂ 
• 1382936-43-7 C₁₇H₁₅ClN₂O₄ 
• 1382936-50-6 C₂₂H₂₅ClN₂O₄ 
• 1382936-47-1 C₁₉H₁₉ClN₂O₄ 
• 1382936-48-2 C₂₀H₂₁ClN₂O₄ 
• 1382936-49-3 C₂₁H₂₃ClN₂O₄ 
• 1382936-51-7 C₂₃H₂₇ClN₂O₄ 
• 1382936-44-8 C₁₈H₁₇ClN₂O₄ 
• 1382936-45-9 C₁₉H₁₉ClN₂O₄ 
• 1382936-46-0 C₂₁H₂₃ClN₂O₄ 

Relevant academic research and scientific papers

5-Azidoepibatidine: An Exceptionally Potent Photoaffinity Ligand for Neuronal α4β2 and α7 Nicotinic Acetylcholine Receptors

Racemic 5-azidoepibatidine [(+/-)-1] was synthesized via 5-aminoepibatidine as a candidate photoaffinity ligand with exceptionally high affinity at the mammalian neuronal nicotinic receptors (Ki values of 0.027 nM for α4β2 and 9.7 nM for α7) and excellent photoreactivity.

ANTI-FIBROTIC PYRIDINONES

This application relates to polycyclic compounds with a pyridinone or pyridinone derivative core including, substituted pyridinones, 5,6- and 6,6- bicyclic heterocycles and substituted pyridine-thiones. This application also discloses methods of preparing these polycyclic compounds, pharmaceutical compositions and medicaments comprising said compounds and methods to treat, prevent or diagnose diseases, disorders or conditions associated with fibrosis.

ANTI-FIBROTIC PYRIDINONES

Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.

Identification of benzoxazole analogs as novel, S1P3 sparing S1P1 agonists

A novel series of benzoxazole-derived S1P1 agonists were designed based on scaffold hopping molecular design strategy combined with computational approaches. Extensive SAR studies led to the discovery of compound 17d as a selective S1P1 agonist (over S1P3) with high CNS penetration and favorable DMPK properties. 17d also demonstrated in vivo pharmacological efficacy to reduce blood lymphocyte in mice after oral administration.

Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin- 7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain

We report the synthesis and SAR of a series of novel azaindole CB 2 agonists. 6-Azaindole 18 showed activity in an acute pain model but was inactive in a chronic model. 18 is a Pgp substrate with low brain penetration. The template was redesign

COMBINATION OF CB2 LIGAND AND PARACETAMOL

Combination of one or more CB2 modulators and paracetamol are useful of treating conditions which are mediated by the activity of CB2 receptors such as an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis, and osteoporosis.

PYRROLOPYRIDINE DERIVATIVES

The present invention relates to novel pyrrolopyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.